Guidant's stent business is being sold to Abbott Laboratories, which is paying $4 billion in cash and acquiring $1.4 billion worth of Boston Scientific stock. The FTC is requiring Abbott, whose participation helped alleviate antitrust concerns,Â to sell the stock within 30 months. Now on tapÂ are someÂ of the most daunting tasks ever faced in the device industry: The first-ever integration of two giant firms, and the placating of CDRH, which has had serious issues with both companies in the past year. Inability to pull off the latter could compromise the firm's ability to introduce new products.
MDDI Online is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.